ScinoPharm Taiwan, Ltd. (TPE:1789)
Taiwan
· Delayed Price · Currency is TWD 20.60
-1.05 (-4.85%)
Mar 9, 2026, 1:30 PM CST
ScinoPharm Taiwan Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3,163 | 3,406 | 3,186 | 3,264 | 2,762 | Upgrade
|
| Revenue Growth (YoY) | -7.13% | 6.91% | -2.39% | 18.16% | -10.40% | Upgrade
|
| Cost of Revenue | 2,067 | 2,106 | 1,970 | 2,013 | 1,482 | Upgrade
|
| Gross Profit | 1,096 | 1,300 | 1,216 | 1,251 | 1,280 | Upgrade
|
| Selling, General & Admin | 490.3 | 518.14 | 543.83 | 573.88 | 685.79 | Upgrade
|
| Research & Development | 497.28 | 459.36 | 357.74 | 271.26 | 305.95 | Upgrade
|
| Operating Expenses | 987.53 | 979.17 | 901.5 | 845.28 | 991.87 | Upgrade
|
| Operating Income | 108.91 | 321.04 | 314.49 | 405.5 | 288.62 | Upgrade
|
| Interest Expense | -9.87 | -8.08 | -9.15 | -7.91 | -6.55 | Upgrade
|
| Interest & Investment Income | 53.38 | 61.52 | 53.63 | 22.12 | 19.38 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 19.23 | -16.98 | 41.27 | -7.91 | Upgrade
|
| Other Non Operating Income (Expenses) | -5.04 | 19.57 | 7.27 | -22.88 | 7.63 | Upgrade
|
| EBT Excluding Unusual Items | 147.38 | 413.27 | 349.26 | 438.09 | 301.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -4.64 | -0.42 | -0.76 | -0.27 | Upgrade
|
| Asset Writedown | - | -1.12 | 0 | 0.63 | 1.38 | Upgrade
|
| Legal Settlements | - | 5.5 | - | - | - | Upgrade
|
| Pretax Income | 147.38 | 413.02 | 348.84 | 437.96 | 302.29 | Upgrade
|
| Income Tax Expense | 10.42 | 73.67 | 61.78 | 84.74 | 58.82 | Upgrade
|
| Net Income | 136.95 | 339.35 | 287.06 | 353.22 | 243.47 | Upgrade
|
| Net Income to Common | 136.95 | 339.35 | 287.06 | 353.22 | 243.47 | Upgrade
|
| Net Income Growth | -59.64% | 18.22% | -18.73% | 45.07% | -13.68% | Upgrade
|
| Shares Outstanding (Basic) | 806 | 791 | 791 | 791 | 791 | Upgrade
|
| Shares Outstanding (Diluted) | 806 | 793 | 792 | 793 | 792 | Upgrade
|
| Shares Change (YoY) | 1.60% | 0.07% | -0.04% | 0.05% | 0.01% | Upgrade
|
| EPS (Basic) | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 | Upgrade
|
| EPS (Diluted) | 0.17 | 0.43 | 0.36 | 0.45 | 0.31 | Upgrade
|
| EPS Growth | -60.39% | 19.21% | -19.41% | 45.07% | -13.68% | Upgrade
|
| Free Cash Flow | 304.62 | 470.74 | -37.3 | 530.51 | 195.4 | Upgrade
|
| Free Cash Flow Per Share | 0.38 | 0.59 | -0.05 | 0.67 | 0.25 | Upgrade
|
| Dividend Per Share | - | 0.350 | 0.300 | 0.360 | 0.480 | Upgrade
|
| Dividend Growth | - | 16.67% | -16.67% | -25.00% | -4.00% | Upgrade
|
| Gross Margin | 34.66% | 38.17% | 38.17% | 38.32% | 46.36% | Upgrade
|
| Operating Margin | 3.44% | 9.43% | 9.87% | 12.42% | 10.45% | Upgrade
|
| Profit Margin | 4.33% | 9.96% | 9.01% | 10.82% | 8.81% | Upgrade
|
| Free Cash Flow Margin | 9.63% | 13.82% | -1.17% | 16.25% | 7.07% | Upgrade
|
| EBITDA | 625.63 | 792.08 | 759.82 | 829.1 | 655.41 | Upgrade
|
| EBITDA Margin | 19.78% | 23.25% | 23.85% | 25.40% | 23.73% | Upgrade
|
| D&A For EBITDA | 516.73 | 471.04 | 445.33 | 423.61 | 366.79 | Upgrade
|
| EBIT | 108.91 | 321.04 | 314.49 | 405.5 | 288.62 | Upgrade
|
| EBIT Margin | 3.44% | 9.43% | 9.87% | 12.42% | 10.45% | Upgrade
|
| Effective Tax Rate | 7.07% | 17.84% | 17.71% | 19.35% | 19.46% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.